Evidence map›Paper›PMID 39475964›Full record

ArticleHuman cell2024

Establishment and characterization of a patient-derived metastatic extraskeletal Ewing sarcoma cell line ES-ZSS-1.

Chenlu Zhang, Mengling Liu, Lijuan Luan, Xi Guo, Yang You, Zhiming Wang, Wei Li, Nanhang Lu, Yingyong Hou, Lili Lu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chenlu Zhang *Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Mengling Liu *Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Lijuan Luan *Department of Pathology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Xi GuoDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Yang YouDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Zhiming WangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Wei LiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Nanhang LuDepartment of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Lili LuDepartment of Biotherapy Center, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Weiqi LuDepartment of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China. lu.weiqi@zs-hospital.sh.cn.
Yuhong ZhouDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China. zhou.yuhong@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The methods available for treating metastatic Ewing sarcoma (ES) are inadequate; thus, innovative therapeutic approaches need to be developed. However, the lack of clinically relevant ES models has hindered the discovery of drugs for this disease. In this study, we established and characterized a patient-derived xenograft (PDX) cell line model, which was constructed using tumor tissue from a patient with metastatic extraskeletal ES. The cells were found to recapitulate the morphological and histopathological features of the patient tumor and were designated as ES-ZSS-1. The cells harbor the characteristic EWSR1-FLI1 infusion and underwent successive passages in vitro. By performing gene expression profiling, we found that the mutation in STAG2 was the most frequent. An increase in Twist1 and epithelial-to-mesenchymal transition (EMT) was recorded. These genetic features might be relevant to metastasis and resistance to chemotherapy. To summarize, the novel patient-derived ES cell line we developed closely mimics the phenotype and genotype of patient tumors, making it a reliable tool for research on metastatic ES.

Indexed as

Epithelial-Mesenchymal TransitionSarcoma, EwingAnimalsBone NeoplasmsCell Line, TumorCohesinsHeterograftsHumansMutationNeoplasm MetastasisNuclear ProteinsOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSTwist-Related Protein 1CohesinsEWSR1-FLI1 fusion protein, humanNuclear ProteinsOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSSTAG2 protein, humanTWIST1 protein, humanTwist-Related Protein 1Epithelial-to-mesenchymal transitionExtraskeletal Ewing sarcomaGenomic characteristicMetastatic and drug resistancePatient-derived cancer cell line

Identifiers

PMID39475964

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.